Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SpringWorks Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for SpringWorks Therapeutics, Inc.

SWTX

SpringWorks Therapeutics, Inc.

About SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics is a biopharmaceutical company focused on developing and commercializing targeted medicines for rare diseases and cancers. Its portfolio includes FDA-approved therapies for desmoid tumors and neurofibromatosis type 1, along with multiple clinical and preclinical candidates targeting tumor types with high unmet medical needs. The company emphasizes precision medicine, strategic partnerships, and innovative small molecule therapies to serve underserved patient populations globally.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from SpringWorks Therapeutics, Inc.

1
1
SpringWorks Therapeutics, Inc. SpringWorks Therapeutics Reports 134% Revenue Growth and Announces Merger with Merck KGaA

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
SpringWorks Therapeutics, Inc. SpringWorks Therapeutics Reports $258.1M Net Loss for Fiscal Year 2024, Improved Product Revenue

Via official filing (AI summary) | over 1 year ago | 0 comments

3
1
SpringWorks Therapeutics, Inc. SpringWorks Therapeutics Reports Decrease in Cash and Cash Equivalents, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments